Versions
- 2024-08-02 (2)
- 2024-08-02 (1)
Keywords
RSV
Nirsevimab
Effectiveness
infants
prophylaxis
Abstract
Respiratory syncytial virus (RSV) predominantly affects young children, with a peak incidence in temperate regions of the northern hemisphere from October to May. Children under 24 months of age are particularly vulnerable because of the immaturity of their lungs and immune systems, which often leads to severe respiratory infections. The World Health Organization (WHO) recognizes RSV as a global health priority.
Recently, Nirsevimab, a long-acting mAb, was authorised to prevent RSV in infants. Our narrative review brings together the field effectiveness data of Nirsevimab available in the literature, highlighting the strengths and weaknesses of the published studies and the prevention opportunities represented by the new preparation. All studies reviewed provide evidence for the effectiveness of immunisation with Nirsevimab in real-world settings, beyond the controlled conditions of clinical trials, and highlight its safety and feasibility. Nirsevimab significantly reduces RSV hospitalisations and ICU admissions. High coverage and high efficacy of immunisation have been reported, although supply issues and variability in studies present challenges. Continued research and surveillance are critical to understanding the long-term effectiveness of Nirsevimab.
Overall, available data provide valuable insights into the efficacy, safety, and impact of immunisation with Nirsevimab in preventing severe RSV infections in infants, highlighting its potential to reduce the burden of RSV-related hospitalisations and improve paediatric health outcomes.
References
1 Azzari C, Baraldi E, Bonanni P, Bozzola E, Coscia A, Lanari M, Manzoni P, Mazzone T, Sandri F, Checcucci Lisi G, Parisi S, Piacentini G, Mosca F. Epidemiology and prevention of respiratory syncytial virus infections in children in Italy. Ital J Pediatr. 2021; 47(1):198. doi: 10.1186/s13052-021-01148-8.
2 Dovizio M, Veronesi C, Bartolini F, Cavaliere A, Grego S, Pagliaro R, Procacci C, Ubertazzo L, Bertizzolo L, Muzii B, Parisi S, Perrone V, Baraldi E, Bozzola E, Mosca F, Esposti LD. Clinical and economic burden of respiratory syncytial virus in children aged 0-5 years in Italy. Ital J Pediatr. 2024; 50(1):57. doi: 10.1186/s13052-024-01628-7.
3 Baraldi E, Lanari M, Manzoni P, Rossi GA, Vandini S, Rimini A, Romagnoli C, Colonna P, Biondi A, Biban P, Chiamenti G, Bernardini R, Picca M, Cappa M, Magazzù G, Catassi C, Urbino AF, Memo L, Donzelli G, Minetti C, Paravati F, Di Mauro G, Festini F, Esposito S, Corsello G. Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infants. Ital J Pediatr. 2014; 40:65. doi: 10.1186/1824-7288-40-65.
4 Sommer C, Resch B, Simões EA Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J. 2011; 5:144-54. doi: 10.2174/1874285801105010144.
5 Barbieri E, Cavagnis S, Scamarcia A, Cantarutti L, Bertizzolo L, Bangert M, Parisi S, Cantarutti A, Baraldi E, Giaquinto C, Baldo V. Assessing the burden of bronchiolitis and lower respiratory tract infections in children ≤24 months of age in Italy, 2012-2019. Front Pediatr. 2023; 11:1143735. doi: 10.3389/fped.2023.1143735.
6 Rha B, Curns AT, Lively JY, Campbell AP, Englund JA, Boom JA, Azimi PH, Weinberg GA, Staat MA, Selvarangan R, Halasa NB, McNeal MM, Klein EJ, Harrison CJ, Williams JV, Szilagyi PG, Singer MN, Sahni LC, Figueroa-Downing D, McDaniel D, Prill MM, Whitaker BL, Stewart LS, Schuster JE, Pahud BA, Weddle G, Avadhanula V, Munoz FM, Piedra PA, Payne DC, Langley G, Gerber SI. Respiratory Syncytial Virus-Associated Hospitalizations Among Young Children: 2015-2016. Pediatrics 2020; 146(1): e20193611. doi: 10.1542/peds.2019-3611.
7 Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, Madhi SA, Omer SB, Simões EAF, Campbell H, Pariente AB, Bardach D, Bassat Q, Casalegno JS, Chakhunashvili G, Crawford N, Danilenko D, Do LAH, Echavarria M, Gentile A, Gordon A, Heikkinen T, Huang QS, Jullien S, Krishnan A, Lopez EL, Markić J, Mira-Iglesias A, Moore HC, Moyes J, Mwananyanda L, Nokes DJ, Noordeen F, Obodai E, Palani N, Romero C, Salimi V, Satav A, Seo E, Shchomak Z, Singleton R, Stolyarov K, Stoszek SK, von Gottberg A, Wurzel D, Yoshida LM, Yung CF, Zar HJ; Respiratory Virus Global Epidemiology Network; Nair H; RESCEU investigators. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022; 399:2047–64. doi: 10.1016/S0140-6736(22)00478-0.
8 Kuhdari P, Brosio F, Malaventura C, Stefanati A, Orsi A, Icardi G, Gabutti G. Human respiratory syncytial virus and hospitalization in young children in Italy. Ital J Pediatr. 2018; 44(1):50. doi: 10.1186/s13052-018-0492-y.
9 Barbati F, Moriondo M, Pisano L, Calistri E, Lodi L, Ricci S, Giovannini M, Canessa C, Indolfi G, Azzari C. Epidemiology of Respiratory Syncytial Virus-Related Hospitalization Over a 5-Year Period in Italy: Evaluation of Seasonality and Age Distribution Before Vaccine Introduction. Vaccines (Basel) 2020; 8(1):15. doi: 10.3390/vaccines8010015.
10 Fortunato F, Campanozzi A, Maffei G, Arena F, Carri VD, Rollo T, Lopalco PL, Martinelli D. Respiratory syncytial virus-associated hospitalizations among children: an Italian retrospective observational study. Ital J Pediatr. 2024; 50(1):45. doi: 10.1186/s13052-024-01617-w.
11 Istituto Superiore di Sanità. Rapporto RespiVirNet Virologico 2024-17. Available at: https://respivirnet.iss.it/pagine/rapportoInflunet.aspx. Accessed on May 14, 2024
12 Sparrow E, Adetifa I, Chaiyakunapruk N, Cherian T, Fell DB, Graham BS, Innis B, Kaslow DC, Karron RA, Nair H, Neuzil KM, Saha S, Smith PG, Srikantiah P, Were F, Zar HJ, Feikin D. WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use. Vaccine 2022; 40(26):3506-10. doi: 10.1016/j.vaccine.2022.02.040.
13 World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2016—conclusions and recommendations. Wkly Epidemiol Rec 2016; 91:265–84. PMID: 27236869.
14 Esposito S, Abu Raya B, Baraldi E, Flanagan K, Martinon Torres F, Tsolia M, Zielen S. RSV Prevention in All Infants: Which Is the Most Preferable Strategy?. Front Immunol. 2022; 13:880368. doi: 10.3389/fimmu.2022.880368.
15 EMA. European Medicines Agency: Beyfortus. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/beyfortus. Accessed on May 14, 2024
16 AIFA. Agenzia Italiana del Farmaco: Beyfortus. Available at: https://www.aifa.gov.it/documents/20142/1805944/DETERMINA_9-2023_BEYFORTUS.pdf. Accessed on May 14, 2024
17 EMA. European Medicines Agency: Abrysvo. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo. Accessed on May 14, 2024
18 AIFA. Agenzia Italiana del Farmaco: Abrysvo. Available at: https://www.aifa.gov.it/documents/20142/2128501/DETERMINA_127-2023_ABRYSVO.pdf. Accessed on May 14, 2024
19 AstraZeneca, Sanofi Pasteur Beyfortus (nirsevimab - alip) [Prescribing information]. 2023 Available at: https://products.sanofi.us/beyfortus/beyfortus.pdf. Accessed on May 14, 2024
20 US, Sanofi-Aventis. Available at: https://www.news.sanofi.us/2023-08-03-U-S-CDC-Advisory-Committee-unanimously-recommends-routine-use-of-Beyfortus-TM-nirsevimab-alip-to-protect-infants-against-RSV-disease. [Online] 03 08 2023. Accessed on May 14, 2024
21 Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Simões EAF, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP; Nirsevimab Study Group. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020; 383(5):415–25. doi: 10.1056/NEJMoa1913556.
22 Zhu Q, McLellan JS, Kallewaard NL, Ulbrandt ND, Palaszynski S, Zhang J, Moldt B, Khan A, Svabek C, McAuliffe JM, Wrapp D, Patel NK, Cook KE, Richter BWM, Ryan PC, Yuan AQ, Suzich JA. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017; 9(388): eaaj1928. doi: 10.1126/scitranslmed.aaj1928.
23 Brady T, Cayatte C, Roe TL, Speer SD, Ji H, Machiesky L, Zhang T, Wilkins D, Tuffy KM, Kelly EJ. . Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection. Front Immunol. 2023; 14:1283120. doi: 10.3389/fimmu.2023.1283120.
24 ACIP. Evidence to Recommendations for Use of Nirsevimab in Infants born during the RSV season or entering their first RSV season. Available at: https://www.cdc.gov/vaccines/acip/recs/grade/Nirsevimab-season1-rsv-infants-children-etr.html. Accessed on May 14, 2024
25 AAP. Recommendations for the Prevention of RSV Disease in Infants and Children. Available at: https://publications.aap.org/redbook/resources/25379/AAP-Recommendations-for-the-Prevention-of-RSV?autologincheck=redirected. Accessed on May 14, 2024
26 Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks, Sánchez PJ, Kotton CN, Mahon BE, Meyer S, Long SS, McMorrow ML. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2023; 72:920–25. doi: 10.15585/mmwr.mm7234a4.
27 Balbi H Nirsevimab: A Review. Pediatr Allergy Immunol Pulmonol. 2024; 37(1):3-6. doi: 10.1089/ped.2024.0025.
28 28. Hammitt LL, Dagan R, Yuan Y,Cots MB, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, Wählby Hamrén U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T; MELODY Study Group Nirsevimab for Prevention of RSV in Healthy. New England Journal of Medicine 2022; 837-46. doi: 10.1056/NEJMoa2110275.
29 Esposito S, Abu-Raya B, Bonanni P, Cahn-Sellem F, Flanagan KL, Martinon Torres F, Mejias A, Nadel S, Safadi MAP, Simon A. Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper. Front Immunol. 2021; 12:708939. doi: 10.3389/fimmu.2021.708939.
30 Muller WJ, Madhi SA, Seoane Nuñez B, Baca Cots M, Bosheva M, Dagan R, Hammitt LL, Llapur CJ, Novoa JM, Saez Llorens X, Grenham A, Kelly EJ, Mankad VS, Shroff M, Takas T, Leach A, Villafana T; MELODY Study Group. Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. N Engl J Med. 2023; 388(16):1533-34. doi: 10.1056/NEJMc2214773.
31 Domachowske J, Madhi SA, Simões EAF, Atanasova V, Cabañas F, Furuno K, Garcia-Garcia ML, Grantina I, Nguyen KA, Brooks D, Chang Y, Leach A, Takas T, Yuan Y, Griffin MP, Mankad VS, Villafana T; MEDLEY Study Group. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. N Engl J Med. 2022; 386(9):892-94. doi: 10.1056/NEJMc2112186.
32 Domachowske J, Wählby Hamren U, Basavaraju B, Koen A, Leach A, Mankad VS, Mori M, Ndibmun C, Soler-Palacin P, Pannaraj PS, Takas T, Villafanaet T. Safety, Tolerability, and Pharmacokinetics of Nirsevimab for the Prevention of RSV Disease in Immunocompromised Children Aged ≤24 Months: Music, an Open Label, Phase 2 Trial. Blood 2023; 142 (Supplement 1): 1173. doi: 10.1182/blood-2023-189096.
33 Simões EAF, Madhi SA, Muller WJ, Atanasova V, Bosheva M, Cabañas F, Baca Cots M, Domachowske JB, Garcia-Garcia ML, Grantina I, Nguyen KA, Zar HJ, Berglind A, Cummings C, Griffin MP, Takas T, Yuan Y, Wählby Hamrén U, Leach A, Villafana T. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023; 7(3):180-89. doi: 10.1016/S2352-4642(22)00321-2.
34 Drysdale SB, Cathie K, Flamein F, Knuf M, Collins AM, Hill HC, Kaiser F, Cohen R, Pinquier D, Felter CT, Vassilouthis NC, Jin J, Bangert M, Mari K, Nteene R, Wague S, Roberts M, Tissières P, Royal S, Faust SN; HARMONIE Study Group. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. N Engl J Med. 2023; 389(26):2425-35. doi: 10.1056/NEJMoa2309189.
35 Hak SF, Venekamp RP, Wildenbeest JG, Bont LJ. Outpatient respiratory syncytial virus infections and novel preventive interventions. Curr Opin Pediatr. 2024; 36(2):171-81. doi: 10.1097/MOP.0000000000001323.
36 Ernst C, Bejko D, Gaasch L, Hannelas E, Kahn I, Pierron C, Del Lero N, Schalbar C, Do Carmo E, Kohnen M, Andlauer E, Hublart P, Masi S, de la Fuente Garcia I, Vergison A, Mossong J. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg. Euro Surveill. 2024; 29(4):2400033. doi: 10.2807/1560-7917.ES.2024.29.4.2400033.
37 Martinón-Torres F, Mirás-Carballal S, Durán-Parrondo C. Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023. Euro Surveill. 2023; 28(49):2300606. doi: 10.2807/1560-7917.ES.2023.28.49.2300606.
38 López-Lacort M, Muñoz-Quiles C, Mira-Iglesias A, López-Labrador FX, Mengual-Chuliá B, Fernández-García C, Carballido-Fernández M, Pineda-Caplliure A, Mollar-Maseres J, Shalabi Benavent M, Sanz-Herrero F, Zornoza-Moreno M, Pérez-Martín JJ, Alfayate-Miguelez S, Pérez Crespo R, Bastida Sánchez E, Menasalvas-Ruiz AI, Téllez-González MC, Esquiva Soto S, Del Toro Saravia C, Sanz-Muñoz I, Eiros JM, Matías Del Pozo V, Toquero-Asensi M, Pastor-Villalba E, Lluch-Rodrigo JA, Díez-Domingo J, Orrico-Sánchez A. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Euro Surveill. 2024; 29(6):2400046. doi: 10.2807/1560-7917.ES.2024.29.6.2400046.
39 Ezpeleta G, Navascués A, Viguria N, Herranz-Aguirre M, Juan Belloc SE, Gimeno Ballester J, Muruzábal JC, García-Cenoz M, Trobajo-Sanmartín C, Echeverria A, Martínez-Baz I, Vera-Punzano N, Casado I, López-Mendoza H, Ezpeleta C, Castilla J. Effectiveness of Nirsevimab Immunoprophylaxis Administered at Birth to Prevent Infant Hospitalisation for Respiratory Syncytial Virus Infection: A Population-Based Cohort Study. Vaccines (Basel). 2024; 12(4):383. doi: 10.3390/vaccines12040383.
40 Mallah N, Ares-Gómez S, Pardo-Seco J, Malvar-Pintos A, Santiago-Pérez MI, Pérez-Martínez O, Otero-Barrós MT, Suárez-Gaiche N, Kramer R, Jin J, Platero-Alonso L, Alvárez-Gil RM, Ces-Ozores OM, Nartallo-Penas V, Mirás-Carballal S, Piñeiro-Sotelo M, González-Pérez JM, Rodríguez-Tenreiro C, Rivero-Calle I, Salas A, Durán-Parrondo C, Martinón-Torres F. Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol. Hum Vaccin Immunother. 2024; 20(1):2348135. doi: 10.1080/21645515.2024.2348135.
41 Ares-Gómez S, Mallah N, Santiago-Pérez MI, Pardo-Seco J, Pérez-Martínez O, Otero-Barrós MT, Suárez-Gaiche N, Kramer R, Jin J, Platero-Alonso L, Alvárez-Gil RM, Ces-Ozores OM, Nartallo-Penas V, Mirás-Carballal S, Piñeiro-Sotelo M, Malvar-Pintos A, González-Pérez JM, Rodríguez-Tenreiro-Sánchez C, Rivero-Calle I, Salas A, Durán-Parrondo C, Martinón-Torres F; NIRSE-GAL study group. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis. 2024; 30:S1473-3099(24)00215-9. doi: 10.1016/S1473-3099(24)00215-9. Epub ahead of print. Erratum in: Lancet Infect Dis. 2024; 23:S1473-3099(24)00355-4. doi: 10.1016/S1473-3099(24)00355-4.
42 Coma E, Martinez-Marcos M, Hermosilla E, Mendioroz J, Reñé A, Fina F, Perramon-Malavez A, Prats C, Cereza G, Ciruela P, Pineda V, Antón A, Ricós-Furió G, Soriano-Arandes A, Cabezas C. Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain). Arch Dis Child. 2024; 10:archdischild-2024-327153. doi: 10.1136/archdischild-2024-327153. Epub ahead of print.
43 Moline HL, Tannis A, Toepfer AP, Williams JV, Boom JA, Englund JA, Halasa NB, Staat MA, Weinberg GA, Selvarangan R, Michaels MG, Sahni LC, Klein EJ, Stewart LS, Schlaudecker EP, Szilagyi PG, Schuster JE, Goldstein L, Musa S, Piedra PA, Zerr DM, Betters KA, Rohlfs C, Albertin C, Banerjee D, McKeever ER, Kalman C, Clopper BR; New Vaccine Surveillance Network Product Effectiveness Collaborators; McMorrow ML, Dawood FS. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024; 73(9):209-14. doi: 10.15585/mmwr.mm7309a4.
44 Paireau J, Durand C, Raimbault S, Cazaubon J, Mortamet G, Viriot D, Milesi C, Daudens-Vaysse E, Ploin D, Tessier S, Vanel N, Chappert JL, Levieux K, Ollivier R, Daoudi J, Coignard B, Leteurtre S, Parent-du-Châtelet I, Vaux S. Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023-January 2024. Influenza Other Respir Viruses. 2024; 18(6):e13311. doi: 10.1111/irv.13311.
45 Consolati A, Farinelli M, Serravalle P, Rollandin C, Apprato L, Esposito S, Bongiorno S. Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d'Aosta Region, Italy, in the 2023-2024 Epidemic Season. Vaccines (Basel). 2024; 12(5):549. doi: 10.3390/vaccines12050549.
46 NIRSE-GAL Available at: https://www.nirsegal.es/en. Accessed on May 20, 2024
47 NCT06042049, Clinical Trial. Available at: https://clinicaltrials.gov/study/NCT06042049?cond=NCT06042049.&rank=1. Accessed on May 22, 2024
48 NCT05110261, Clinical Trial. Available at: https://clinicaltrials.gov/study/NCT05110261?cond=NCT05110261&rank=1. Accessed on May 22, 2024
49 NCT06030505, Clinical Trial. Available at: https://clinicaltrials.gov/study/NCT06030505?cond=NCT06030505&rank=1. Accessed on May 22, 2024
50 NCT06185647, Clinical Trial. Available at: https://clinicaltrials.gov/study/NCT06185647?cond=NCT06185647&rank=1. Accessed on May 22, 2024
51 NCT06325332, Clinical Trial. Available at: https://clinicaltrials.gov/study/NCT06325332?cond=NCT06325332&rank=1. Accessed on May 22, 2024
52 Gebretekle GB, Yeung MW, Ximenes R, Cernat A, Simmons AE,et al. Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants. MedRxiv 2024; 24304675; doi: https://doi.org/10.1101/2024.03.21.24304675 Available at: https://www.medrxiv.org/content/10.1101/2024.03.21.24304675v1. Accessed on May 16, 2024